Angiogenesis regulatory factors in the vitreous from patients with proliferative diabetic retinopathy

[1]  Thomas Hawighorst,et al.  CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo , 2010, Breast Cancer Research and Treatment.

[2]  Florence T. H. Wu,et al.  A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use , 2009, Journal of cellular and molecular medicine.

[3]  P. Bornstein,et al.  Enhanced Angiogenesis and Reduced Contraction in Thrombospondin-2–null Wounds Is Associated With Increased Levels of Matrix Metalloproteinases-2 and −9, and Soluble VEGF , 2009, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[4]  M. Matsumura,et al.  Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. , 2008, Ophthalmology.

[5]  J. Van Damme,et al.  Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. , 2008, European cytokine network.

[6]  W. Sessa,et al.  Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis. , 2008, The American journal of pathology.

[7]  J. Quigley,et al.  Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis , 2007, Proceedings of the National Academy of Sciences.

[8]  J. Lawler,et al.  Thrombospondin-based antiangiogenic therapy. , 2007, Microvascular research.

[9]  M. Shibuya.  Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. , 2006, Journal of biochemistry and molecular biology.

[10]  M. Luisa Iruela-Arispe,et al.  Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors , 2005, The Journal of cell biology.

[11]  R. Silverstein,et al.  The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. , 2005, Matrix biology : journal of the International Society for Matrix Biology.

[12]  M. Detmar,et al.  Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. , 2004, The American journal of pathology.

[13]  M. Capogrossi,et al.  Marked inhibition of retinal neovascularization in rats following soluble‐flt‐1 gene transfer , 2004, The journal of gene medicine.

[14]  K. Matsuda,et al.  An N-terminal 80 kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo. , 2003, The Journal of investigative dermatology.

[15]  Yong Y. He,et al.  Differential Regulation of Thrombospondin-1 and Thrombospondin-2 After Focal Cerebral Ischemia/Reperfusion , 2003, Stroke.

[16]  C. E. Stiles,et al.  Thrombospondin 2 Inhibits Microvascular Endothelial Cell Proliferation by a Caspase-independent Mechanism , 2002, Molecular biology of the cell.

[17]  P. Bornstein,et al.  Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. , 2001, The American journal of pathology.

[18]  M. Detmar,et al.  Thrombospondin‐2 plays a protective role in multistep carcinogenesis: a novel host anti‐tumor defense mechanism , 2001, The EMBO journal.

[19]  M. Matsumura,et al.  Expression of cytokines and transcription factors in photocoagulated human retinal pigment epithelial cells , 2001, Graefe's Archive for Clinical and Experimental Ophthalmology.

[20]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[21]  M. Detmar,et al.  Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Bornstein,et al.  Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. , 1999, The Journal of investigative dermatology.

[23]  W. Benedict,et al.  Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. , 1999, Science.

[24]  D. McLeod,et al.  Growth factor staining patterns in the pig retina following retinal laser photocoagulation , 1999, The British journal of ophthalmology.

[25]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[26]  A. Pfeiffer,et al.  New concepts in pathogenesis and treatment of diabetic retinopathy. , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.